| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTGFRN |
| Uniprot No | Q9P2B2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-879aa |
| 氨基酸序列 | MGRLASRPLLLALLSLALCRGRVVRVPTATLVRVVGTELVIPCNVSDYDGPSEQNFDWSFSSLGSSFVELASTWEVGFPAQLYQERLQRGEILLRRTANDAVELHIKNVQPSDQGHYKCSTPSTDATVQGNYEDTVQVKVLADSLHVGPSARPPPSLSLREGEPFELRCTAASASPLHTHLALLWEVHRGPARRSVLALTHEGRFHPGLGYEQRYHSGDVRLDTVGSDAYRLSVSRALSADQGSYRCIVSEWIAEQGNWQEIQEKAVEVATVVIQPSVLRAAVPKNVSVAEGKELDLTCNITTDRADDVRPEVTWSFSRMPDSTLPGSRVLARLDRDSLVHSSPHVALSHVDARSYHLLVRDVSKENSGYYYCHVSLWAPGHNRSWHKVAEAVSSPAGVGVTWLEPDYQVYLNASKVPGFADDPTELACRVVDTKSGEANVRFTVSWYYRMNRRSDNVVTSELLAVMDGDWTLKYGERSKQRAQDGDFIFSKEHTDTFNFRIQRTTEEDRGNYYCVVSAWTKQRNNSWVKSKDVFSKPVNIFWALEDSVLVVKARQPKPFFAAGNTFEMTCKVSSKNIKSPRYSVLIMAEKPVGDLSSPNETKYIISLDQDSVVKLENWTDASRVDGVVLEKVQEDEFRYRMYQTQVSDAGLYRCMVTAWSPVRGSLWREAATSLSNPIEIDFQTSGPIFNASVHSDTPSVIRGDLIKLFCIITVEGAALDPDDMAFDVSWFAVHSFGLDKAPVLLSSLDRKGIVTTSRRDWKSDLSLERVSVLEFLLQVHGSEDQDFGNYYCSVTPWVKSPTGSWQKEAEIHSKPVFITVKMDVLNAFKYPLLIGVGLSTVIGLLSCLIGYCSSHWCCKKEVQETRRERRRLMSMEMD |
| 预测分子量 | 98,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PTGFRN重组蛋白的参考文献概要(文献标题和作者为虚构示例，仅供格式参考)：
1. **标题**: *PTGFRN重组蛋白在肿瘤细胞迁移中的作用机制研究*
**作者**: Zhang L et al.
**摘要**: 研究通过大肠杆菌表达系统制备PTGFRN重组蛋白，发现其通过调控整合素信号通路抑制肺癌细胞的迁移能力，为肿瘤治疗提供潜在靶点。
2. **标题**: *CD315/PTGFRN重组蛋白的晶体结构解析及功能域分析*
**作者**: Watanabe K et al.
**摘要**: 首次报道PTGFRN重组蛋白的X射线晶体结构，揭示其跨膜结构域与配体结合的关键氨基酸位点，为设计靶向药物提供结构基础。
3. **标题**: *基于PTGFRN重组蛋白的细胞外囊泡载药系统开发*
**作者**: Chen X et al.
**摘要**: 利用哺乳动物细胞表达的PTGFRN重组蛋白修饰外泌体，显著提高纳米颗粒对脑部肿瘤的靶向递送效率，验证其作为药物载体的应用潜力。
(注：以上内容为模拟创作，实际文献需通过PubMed/Google Scholar等平台用关键词"PTGFRN recombinant protein"或"CD315 protein expression"检索)
PTGFRN (Prostaglandin F2 Receptor Negative Regulator), also known as CD9P-1 or FPRP, is a transmembrane protein encoded by the PTGFRN gene. It belongs to the immunoglobulin superfamily and plays a multifaceted role in cellular adhesion, signaling, and structural organization. Naturally expressed in various tissues, PTGFRN interacts with integrins, tetraspanins (e.g., CD9. CD81), and other membrane proteins to regulate cell-matrix interactions, motility, and intracellular communication. It is particularly noted for stabilizing protein complexes at cell surfaces and modulating extracellular matrix remodeling.
Recombinant PTGFRN protein is engineered for research and therapeutic applications. Produced using expression systems like mammalian cells or HEK293 lines, it retains functional domains for ligand binding and partner protein interactions. This engineered form enables controlled studies of PTGFRN’s biological mechanisms, bypassing the complexity of isolating it from native tissues. Researchers use it to investigate its role in cancer progression, immune regulation, and tissue repair, as PTGFRN overexpression is linked to tumor metastasis and altered immune responses.
In drug development, recombinant PTGFRN serves as a tool for screening molecules targeting its interactions or as a scaffold for therapeutic antibodies. Its involvement in exosome biogenesis and viral entry mechanisms also positions it as a candidate for vaccine design or antiviral strategies. Structural studies using recombinant protein help map binding sites and design inhibitors. Despite its emerging significance, PTGFRN’s full functional spectrum remains under exploration, with recombinant variants accelerating discoveries in cell biology and precision medicine.
×
